News

Public · Published

Boston Scientific Reports Q3 2026 Sales of $5.14 Billion, Adjusted EPS of $0.73

Boston Scientific reported third-quarter 2026 net sales of $5.14 billion, up 1.5% from a year earlier, with adjusted earnings per share of $0.73 versus $0.75 previously. The company lowered its full-year 2026 outlook to about 4.25% reported sales growth and adjusted earnings per share of $3.16 to $3.18.

Published:

Updated:

What happened

Boston Scientific reported third-quarter 2026 net sales of $5.14 billion, up 1.5% from a year earlier, with adjusted earnings per share of $0.73 versus $0.75 previously. The company lowered its full-year 2026 outlook to about 4.25% reported sales growth and adjusted earnings per share of $3.16 to $3.18.

Confirmed

Global impact / market context

Slower sales growth and lower profit per share than a year earlier suggest the company is selling more but keeping less profit, while the cut to its full-year outlook tells investors management now expects weaker results ahead, which can pressure the stock and reduce confidence in future earnings.

Analyst inference

Growth was uneven by region and business: U.S. sales rose just 0.5% and APAC fell 0.6%, while LACA grew 16.0%, and MedSurg expanded only 0.6%. This mix matters because slower high-growth segments can limit future revenue and profit, shaping how investors value the shares.

Analyst inference

What to watch

  1. Watch whether fourth-quarter sales and adjusted earnings per share land within the lowered full-year guidance of about 4.25% reported sales growth and $3.16 to $3.18 per share, since missing it would further weaken confidence. Confirmed
  2. Watch for updates on the Elite AF trial, which evaluates a Boston Scientific device, because trial progress could affect future product revenue and how investors judge the company's research pipeline. Proposed
  3. Watch U.S. and APAC sales trends, since U.S. growth of 0.5% and APAC decline of 0.6% were the weakest regions and could keep overall revenue growth below the company's historical pace. Analyst inference

Evidence

  • Original source link unavailable